Month: June 2023

VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today commented on its previously announced engagement with several parties that have submitted unsolicited indications of interest regarding various forms of potential transactions involving Teck’s steelmaking coal business. Teck’s Board of Directors and independent Special Committee, in accordance with its fiduciary duties to shareholders, are continuing to consider and evaluate all actionable, value-accretive proposals received relating to Teck’s steelmaking coal business to determine whether they are in the best interests of Teck’s shareholders and all stakeholders. As part of this ongoing review, Teck confirms it is engaging with Glencore around their proposal regarding the steelmaking coal business....

Inside information: GF Announces a Voluntary Recommended Public Cash Tender Offer for all Shares in Uponor at EUR 28.85 per Share Uponor Corporation, Inside Information, June 12, 2023, 8.25 a.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THIS TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. Georg Fischer Ltd. (“GF” or the “Offeror”) and Uponor Corporation (“Uponor” or the “Company”) have, on June 12, 2023, entered into the combination agreement (the “Combination Agreement”) pursuant to which the Offeror will make a voluntary recommended public all-cash tender offer for all the issued and outstanding shares (the “Shares” or, individually, a “Share”) that are not held by...

KOKOMO, Ind., June 11, 2023 (GLOBE NEWSWIRE) — Haynes International, Inc. (NASDAQ GM: HAYN), a leading developer, manufacturer and marketer of technologically advance high-performance alloys (the “Company”), announced today that yesterday morning the Company began experiencing a network outage indicative of a cybersecurity threat. Upon discovery, the Company engaged third-party specialists to assist in investigating the source of this outage, confirm its impact on the Company’s systems, and to securely restore full functionality to the Company’s systems as soon as possible. The Company’s investigation into this matter is ongoing. Please contact Angela Kohlheim at investor_relations@haynesintl.com with any questions. About Haynes International Haynes International, Inc is a leading developer, manufacturer, and marketer of technologically...

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE) Across all patients (n=10), a single dose of NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate through the latest follow-up All patients who achieved greater than 60% plasma kallikrein reduction (n=9) remain completely attack free following the 16-week primary observation period through the latest follow-up; longest attack-free interval is 13.0 months and ongoing All patients who discontinued concomitant long-term HAE prophylaxis treatment after NTLA-2002 administration (n=6) have reported no HAE attacks since discontinuation through the latest follow-up NTLA-2002 has been well tolerated at all dose levels Intellia to host investor webcast on Monday, June 12, at 8 a.m. ETCAMBRIDGE, Mass.,...

DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®. Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.DATE/TIMES: MONDAY, JUNE 12, 2023  10:00 a.m. – 11:00 a.m.   LOCATION:  MannKind  40...

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib – – Ziftomenib monotherapy drives durable remissions, with median DoR of 8.2 months – – Data suggest ziftomenib is less likely to induce menin resistance mutations – – Enrollment in Phase 2 registration-directed trial in NPM1-mutant AML continues to outperform projections – – First combination study in NPM1-mutant and KMT2A-rearranged AML on track to dose first patients this quarter – – Management to host virtual investor event at 8:00 a.m. ET on Monday, June 12 – SAN DIEGO, June 11, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial through Month 12 Implant observed to bioresorb consistently at about eight to nine months in trial, informing potential redosing timeline Investor/analyst conference call to discuss results to be held on Monday, June 12, at 8:30 a.m. ET BEDFORD, Mass., June 10, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced 12-month data from its Phase 1 U.S. clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel...

Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placeboZUG, Switzerland, June 11, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two presentations highlighting data from RAPIDe-1, a Phase 2 study of PHVS416 (deucrictibant immediate-release capsules) for the on-demand treatment of HAE attacks, included in the “Flash Talks on Angioedema” session at the European Academy of Allergy & Clinical Immunology (EAACI) Hybrid Congress 2023, taking place in Hamburg, Germany, from June 9-11, 2023. Presentation details:Title: Treatment with Oral...